Q-omics provides the consensus-scored PPP1R14A profile across patient tissues and cancer cell-line models. PPP1R14A expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, PPP1R14A is differentially expressed in 15, with the highest sampling consensus in KICH. Additionally, PPP1R14A protein abundance shows 27,048 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight KIRP, KICH, and GBM as cancer lineages where PPP1R14A shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PPP1R14A — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PPP1R14A survival associations across molecular data types. PPP1R14A RNA expression shows survival associations in the most cancer types (21), followed by mutation status (2) and mass-spec protein abundance (7). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PPP1R14A RNA expression–survival associations across cancer types. High PPP1R14A expression shows unfavorable associations in KIRP, ACC, CESC, STAD, READ and LUSC. The KIRP Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRP as the clearest survival context for PPP1R14A RNA expression.
This table summarizes PPP1R14A tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15, while mass-spec protein shows differences in 7. The strongest signals are observed in KICH for RNA and COAD for protein.
This table ranks reproducible tumor–normal expression differences for PPP1R14A. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PPP1R14A shows lower tumor expression in KICH, COAD, BLCA, LUSC, LUAD and KIRP. The KICH box plot shows higher PPP1R14A RNA expression in normal versus tumor tissue (log2 FC = −2.940, t-test p < 0.001).
This table shows molecular features associated with PPP1R14A in patient tissues and cancer cell lines. In patient samples, PPP1R14A shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, PPP1R14A RNA and mutation anchors are most strongly linked to RNA-expression features, especially in CNS, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and BREAST.
